wb 4101 has been researched along with Cardiac Hypertrophy in 1 studies
N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine bearing a [(2',6'-dimethoxyphenoxy)ethylamino]methyl group at position 2. An alpha1A-adrenergic selective antagonist.
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mier, K | 1 |
| Kemken, D | 1 |
| Katus, HA | 1 |
| Richardt, G | 1 |
| Kurz, T | 1 |
1 other study available for wb 4101 and Cardiac Hypertrophy
| Article | Year |
|---|---|
Adrenergic activation of cardiac phospholipase D: role of alpha(1)-adrenoceptor subtypes.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Cardiomegaly; Clonidine; Dioxane | 2002 |